Nov 12 (Reuters) - MethylGene Inc:
* Reports third quarter 2010 financial results and provides clinical update for
mgcd265
* Auto Alert - Q3 loss per share C$0.12
* Auto Alert - Q3 revenue C$587,000 versus C$485,000
* Says in the phase 1/2 docetaxel-arm of trial 265-103 the maximum-tolerated
dose (mtd) has been reached
* Says in both trials 265-101 and 265-102, mgcd265 is well tolerated
* Says current cash, cash equivalents sufficient to carry out planned research,
operations to the end of Q1 of 2011
((Auto Alerts are automatically generated headlines. Please help us in our effort to make this service as accurate as possible. If you ever notice a machine-generated error, contact our headlines team at blr.newsroom@reuters.com))
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Reports third quarter 2010 financial results and provides clinical update for
mgcd265
* Auto Alert - Q3 loss per share C$0.12
* Auto Alert - Q3 revenue C$587,000 versus C$485,000
* Says in the phase 1/2 docetaxel-arm of trial 265-103 the maximum-tolerated
dose (mtd) has been reached
* Says in both trials 265-101 and 265-102, mgcd265 is well tolerated
* Says current cash, cash equivalents sufficient to carry out planned research,
operations to the end of Q1 of 2011
((Auto Alerts are automatically generated headlines. Please help us in our effort to make this service as accurate as possible. If you ever notice a machine-generated error, contact our headlines team at blr.newsroom@reuters.com))
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.